Vertex Pharmaceuticals Incorporated · Cambridge, MA United States (NASDAQ: VRTX)
| 130 Waverly St. | Phone: 617-444-6100 |
| Cambridge, MA | Fax: 617-444-6680 |
| 02139 | |
| United States | 
Map This Company |
Vertex Pharmaceuticals Incorporated Rankings
| S&P 400 |
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Vertex Pharmaceuticals aims to cure patients with previously incurable diseases. The biotechnology company uses an integrated, multidisciplinary approach -- employing biophysics, computer-based modeling, and functional genomics -- to speed up the discovery and development of new drugs. Its first commercial product, Incivek (telaprevir) for hepatitis C virus (HCV), was launched in 2011, and a second drug for cystic fibrosis, Kalydeco, was launched in 2012. The company has other drugs in development, including additional treatments for HCV and cystic fibrosis, as well as epilepsy and rheumatoid arthritis.
Vertex Pharmaceuticals Incorporated Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: VRTX Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 2,000 |
Executives
102 executives listed for Vertex Pharmaceuticals Incorporated's Cambridge, MA location.
| Chairman, President, and CEO | Matthew Emmens | |
|---|---|---|
| EVP and CFO | Ian Smith | |
| EVP and Chief Commercial Officer | Nancy Wysenski |